Removal of the anticoagulant activities of the low molecular weight heparin fractions and fragments with flavobacterial heparinase.
Recently, the development of low molecular weight heparin fractions and fragments (LMHF) as potential antithrombotic agents has gained increased attention. However, the lack of antagonists to neutralize the anticoagulant effects of these drugs may seriously exclude them from possible uses in extracorporeal therapy. This is mainly because of the concern that the high dosage of the drugs employed in extracorporeal therapy could lead to serious bleeding risks. Our earlier work has demonstrated that immobilized heparinase can remove polydisperse heparin both in vitro and in vivo. To examine whether such a system may be used as a novel approach to neutralize the anticoagulant effects of LMHF, different LMHF were tested using heparinase. In vitro data showed that both the APTT and anti-FXa activities of the LMHF including Kabi 2165, PK 10169, Cy 216 and CY 222 were nearly completely eliminated by heparinase in less than 20 min. This study suggests that an immobilized heparinase system may be an useful element for the acceptance of the LMHF for their use in extracorporeal therapy.
D000925:Anticoagulants / Q000502:physiology; D003864:Depression, Chemical; D005170:Factor X / Q000037:antagonists & inhibitors; D015951:Factor Xa; D005417:Flavobacterium / Q000201:enzymology; D006493:Heparin / Q000378:metabolism / Q000627:therapeutic use*; D019763:Heparin Lyase; D006801:Humans; D009500:Neutralization Tests; D010314:Partial Thromboplastin Time; D011133:Polysaccharide-Lyases / Q000494:pharmacology*; D011479:Protamines / Q000494:pharmacology; D011487:Protein Conformation
D000925:Anticoagulants; D011479:Protamines; D005170:Factor X; D006493:Heparin; D015951:Factor Xa; D011133:Polysaccharide-Lyases; D019763:Heparin Lyase